Figures computed from official regulatory filings — .
Ownershipinsiders 2.27% · institutions 0% · short 6.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Kiromic Biopharma, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; Procel, which is in clinical trial in combination with low-dose radiation to treat PD-L1 positive solid malignancies; ALEXIS-ISO-1, which is in clinical trial to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies; and ALEXIS-PRO-1, which is in clinical trial to evaluate Procel in patients with PD-L1 positive solid malignancies. It has a license agreement with Longwood University. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. On March 21, 2025, Kiromic BioPharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
15 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| BERSANI PIETRO | Buy | $5.5K | conv 53Cluster |
| SEC |
| BERSANI PIETRO | Buy | $1.9K | conv 42ClusterUnusual size | SEC |
| Hungerford Briantrack record | Buy | $580.5 | conv 47ClusterUnusual size | SEC |
| Hungerford Briantrack record | Buy | $8.2K | conv 69ClusterUnusual size | SEC |
| Hungerford Briantrack record | Buy | $3.5K | conv 66Cluster | SEC |
| Misajon Pamela | Buy | $4K | conv 42Cluster | SEC |
| Hungerford Briantrack record | Buy | $2.6K | conv 51Cluster | SEC |
| Misajon Pamela | Buy | $1.3K | conv 41Cluster | SEC |
| BERSANI PIETRO | Buy | $9.7K | conv 49ClusterFirst in 12mo | SEC |
| Hungerford Briantrack record | Buy | $3.2K | conv 58ClusterFirst in 12mo | SEC |
| Misajon Pamela | Buy | $5K | conv 41First in 12mo | SEC |
| BERSANI PIETRO | Buy | $9.8K | conv 41Cluster | SEC |
| NAGEL MICHAEL | Buy | $3.3K | conv 51ClusterFirst in 12mo | SEC |
| Ralston Shannon | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | First in 12mo | SEC |
| Hungerford Briantrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hungerford Briantrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hungerford Briantrack record | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BERSANI PIETRO | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Catlin Michael | Award | n/a (No price was disclosed in the filing) | SEC |
| Misajon Pamela | Award | n/a (No price was disclosed in the filing) | SEC |
| NAGEL MICHAEL | Award | n/a (No price was disclosed in the filing) | SEC |
| NAGEL MICHAEL | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Misajon Pamela | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hungerford Briantrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Catlin Michael | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |